Coherus Oncology, Inc. Stockholders Equity

• Coherus Oncology, Inc. showed an increase of +146.2% in Stockholders Equity from 2024 to 2025.
• This data is from Coherus Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
• XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q3 2014: -$151.83 million | Q1 2015: $38.15 million | Q2 2015: $96.75 million | Q3 2015: $40.57 million | Q1 2016: -$66.01 million | Q2 2016: -$60.89 million | Q3 2016: $32.87 million | Q1 2017: $78.18 million | Q2 2017: $32.14 million | Q3 2017: $56.20 million | Q1 2018: -$1.79 million | Q2 2018: $63.17 million | Q3 2018: $12.39 million | Q1 2020: $157.28 million | Q2 2020: $213.38 million | Q3 2020: $255.73 million | Q1 2021: $127.67 million | Q2 2021: $156.22 million | Q3 2021: $130.76 million | Q1 2022: $12.56 million | Q2 2022: -$22.63 million | Q3 2022: -$97.13 million | Q1 2023: -$196.51 million | Q2 2023: -$174.76 million | Q3 2023: -$133.60 million | Q1 2024: -$81.84 million | Q2 2024: -$84.11 million | Q3 2024: -$87.97 million | Q1 2025: -$183.47 million | Q2 2025: $119.83 million | Q3 2025: $87.77 million.
• Over the full 13 years of available data (2013 to 2025), Coherus Oncology, Inc.'s Stockholders Equity has grown by 162.9%.
• Historical annual values: Fiscal year 2025: $61.01 million | Fiscal year 2024: -$131.99 million | Fiscal year 2023: -$193.43 million | Fiscal year 2022: -$137.42 million | Fiscal year 2021: $97.73 million | Fiscal year 2020: $280.97 million | Fiscal year 2019: $105.21 million | Fiscal year 2018: -$38.59 million | Fiscal year 2017: $30.54 million | Fiscal year 2016: $20.53 million | Fiscal year 2015: -$6.21 million | Fiscal year 2014: $66.80 million | Fiscal year 2013: -$97.08 million.
• Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: August 5, 2026